A second generation BTK inhibitor, acalabrutinib, was recently approved in Canada in 2019 and is now reimbursed by all provinces for previously untreated CLL as well as for CLL patients who have received at least one prior therapy [6,7]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.